

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) [[New]] A peptide[[,]] comprising an amino acid sequence selected from the group that consists of

DVFMKGLSMAKEGV (SEQ ID NO: 1)

VFMKGLSMAKEGV (SEQ ID NO: 2)

FMKGLSMAKEGV (SEQ ID NO: 3)

MKGLSMAKEGV (SEQ ID NO: 4)

KGLSMAKEGV (SEQ ID NO: 5)

GLSMAKEGV (SEQ ID NO: 6)

LSMAKEGV (SEQ ID NO: 7)

SMAKEGV (SEQ ID NO: 8)

MAKEGV (SEQ ID NO: 9)

AKEGV (SEQ ID NO: 10)

KEGV (SEQ ID NO: 11)

MDVFMKGLSMAKEG (SEQ ID NO: 12)

MDVFMKGLSMAKE (SEQ ID NO: 13)

MDVFMKGLSMAK (SEQ ID NO: 14)

MDVFMKGLSMA (SEQ ID NO: 15)

MDVFMKGLSM (SEQ ID NO: 16)

MDVFMKGLS (SEQ ID NO: 17)

MDVFMKGL (SEQ ID NO: 18)

MDVFMKG (SEQ ID NO: 19)

MDVFMK (SEQ ID NO: 20)
MDVFM (SEQ ID NO: 21)
MDVF (SEQ ID NO: 22)
DVFMKGLSMAKEG (SEQ ID NO: 23)
DVFMKGLSMAKE (SEQ ID NO: 24)
DVFMKGLSMAK (SEQ ID NO: 25)
DVFMKGLSMA (SEQ ID NO: 26)
DVFMKGLSM (SEQ ID NO: 27)
DVFMKGLS (SEQ ID NO: 28)
DVFMKGL (SEQ ID NO: 29)
DVFMKG (SEQ ID NO: 30)
DVFMK (SEQ ID NO: 31)
DVFM (SEQ ID NO: 32)
DVF (SEQ ID NO: 33)
GLSMAKEG (SEQ ID NO: 34)
GLSMAKE (SEQ ID NO: 35)
GLSMAK (SEQ ID NO: 36)
GLSMA (SEQ ID NO: 37)
GLSM (SEQ ID NO: 38)
GLS (SEQ ID NO: 39)
GL (SEQ ID NO: 40)
LSMAKEG (SEQ ID NO: 41)
LSMAKE (SEQ ID NO: 42)
LSMAK (SEQ ID NO: 43)
LSMA (SEQ ID NO: 44)
LSM (SEQ ID NO: 45)
LS (SEQ ID NO: 46)

2. (currently amended) The peptide ~~Peptides~~ according to claim 1, whereby the individual components are L-amino acids.

3. (currently amended) The peptide ~~Peptides~~ according to claim 1, whereby the individual amino acids are D-amino acids.

4. (currently amended) The peptide ~~Peptides~~ according to claim 1, in which the amino acid proline is substituted in the N-terminal position.

5. (currently amended) The peptide ~~Peptides~~ according to claim 1, in which the amino acid proline is substituted in the C-terminal position.

6. (currently amended) The peptide ~~Peptides~~ according to claim 1, in which the amino acid proline is substituted in the N-terminal position and in the C-terminal position.

7. (currently amended) The peptide ~~Peptides~~ according to claim 1, which are acetylated in the N-terminal position.

8. (currently amended) The peptide ~~Peptides~~ according to claim 1, which are amidated in the C-terminal position.

9. (currently amended) The peptide ~~Peptides~~ according to claim 7, which are acetylated in the N-terminal position and amidated in the C-terminal position.

10. (currently amended) The peptide ~~Peptides~~ according to claim 1, characterized in that the amino acid valine (V) is replaced by the amino acid proline (P).

11. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent for use in the therapy of diseases in which the increased occurrence of free radicals plays a pathophysiological role, characterized by at least one peptide according to claim 1.

12. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent for use in the therapy of diseases with acute hypoxia or ischemia in an organ system of the body, in particular in the central nervous system, characterized by at least one peptide according to claim 1.

13. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent for use in the therapy of Recklinghausen-Appelbaum diseases, such as the Hallervorden-Spatz disease, characterized by at least one peptide according to claim 1.

14. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent for use in the therapy of neurodegenerative diseases, in particular Alzheimer's disease, the Lewy Body variant of Alzheimer's disease, Parkinson's disease, the multisystem atrophy, the Lewy Body dementia or Huntington's chorea, and all states similar to these neurodegenerative diseases, characterized by at least one peptide according to claim 1 as an active ingredient.

15. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for oral administration.

16. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for rectal administration.

17. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for administration by inhalation.

18. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for transdermal administration.

19. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for transmucosal administration.

20. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for administration via active ingredient-containing implants.

21. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for intracerebroventricular administration.

22. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for administration by injection.

23. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for transnasal administration.

24. (currently amended) A pharmaceutical ~~Pharmaceutical~~ agent according to claim 11, which is prepared for administration by infusion.

25-26. (canceled)